[at Wall St. Cheat Sheet] – The Carlyle Group is in talks with Johnson & Johnson, hoping to purchase the company’s blood testing unit in a deal that could be worth $4 billion.
Read more on this.
Johnson & Johnson (JNJ), currently valued at $259.74B, started trading this morning at $92.18.
A quick look at the market, the company’s traded between $91.85 to $92.39 and has traded between $69.18 and $95.99 over the past year.
JNJ shares are currently priced at 16.79x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 4.14x forward p/e ratio.
The company pays shareholders $2.64 per share annually in dividends, yielding 2.90%.
In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $1.20 per share, which would be $0.01 better than the year-ago quarter and a $0.02 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $5.48, which would be a $0.38 improvement when compared to the last year’s annual results.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $17.94 Billion. If realized, that would be a 2.16% increase over the year-ago quarter.
More recently, Deutsche Bank downgraded JNJ from Buy to Hold (Jul 17, 2013). Previously, Deutsche Bank upgraded JNJ from Hold to Buy.
Investors should keep in mind is that the average price target is $96.96, which is 5.19% above where the stock opened this morning.
Johnson & Johnson (NYSE:JNJ), together with its subsidiaries, engages in the research and development, manufacture and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics.
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .